Receptor status | Case–case study, odds ratio | ||||||||
---|---|---|---|---|---|---|---|---|---|
E2 (pmol I−1) | E2/SHBG | E1 (pmol l−1) | E1S (pmol l−1) | E1S/E1 | AD (nmol l−1) | TE (nmol l−1) | TE/SHBG | BMI (kg/m2) | |
(ER+)/(ER−) | 0.82 | 1.09 | 1.66** | 1.26 | 0.72 | 1.24 | 1.50 | 1.20 | 1.12 |
(PR+)/(PR−) | 1.09 | 1.36 | 1.5* | 1.08 | 0.65* | 1.52* | 1.36 | 1.39 | 1.66* |
(ER+/PR+)/(ER−/PR−) | 0.84 | 1.18 | 1.77* | 1.23 | 0.66 | 1.31 | 1.56 | 1.29 | 1.70* |
(HER2+)/(HER2−) | 1.32 | 1.99 | 0.53* | 2.44** | 3.12*** | 0.81 | 0.99 | 1.04 | 0.48* |
(HER2+/ER−/PR−)/(HER2−/ER−/PR−) | 0.25 | 1.00 | 0.56 | 1.08 | 2.08 | 0.71 | 1.13 | 1.33 | 0.46 |
(HER2−/ER+/PR+)/(HER2−/ER+/PR−) | 1.67 | 1.99 | 1.38 | 1.07 | 0.58 | 1.51 | 1.11 | 1.43 | 1.89 |
(HER2+/ER+/PR+)/(HER2−/ER−/PR−) | 2.00 | 9.00* | 1.50 | 17.00** | 6.00* | 2.14 | 11.60* | 2.25 | 0.42 |
(HER2+/ER+/PR+)/(HER2−/ER+/PR+) | 6.94 | 7.00 | 0.83 | 17.00* | 31.19* | 1.22 | 1.66 | 2.25 | nd |